Dumac, Inc. Syndax Pharmaceuticals Inc Transaction History
Dumac, Inc.
- $26.4 Million
- Q2 2024
Shares
2 transactions
Others Institutions Holding SNDX
# of Institutions
201Shares Held
87MCall Options Held
268KPut Options Held
76.8K-
Black Rock Inc. New York, NY7.91MShares$150 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA7.34MShares$139 Million0.03% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.72MShares$108 Million9.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.8MShares$90.9 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.89MShares$73.6 Million1.09% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $1.07B
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...